Premium
Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia
Author(s) -
Okusanya BO,
Oladapo OT,
Long Q,
Lumbiga P,
Carroli G,
Qureshi Z,
Duley L,
Souza JP,
Gülmezoglu AM
Publication year - 2016
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/1471-0528.13753
Subject(s) - eclampsia , pharmacokinetics , dosing , medicine , magnesium , regimen , bioavailability , pharmacology , pregnancy , chemistry , genetics , organic chemistry , biology
Background The pharmacokinetic basis of magnesium sulphate (Mg SO 4 ) dosing regimens for eclampsia prophylaxis and treatment is not clearly established. Objectives To review available data on clinical pharmacokinetic properties of Mg SO 4 when used for women with pre‐eclampsia and/or eclampsia. Search strategy MEDLINE , EMBASE , CINAHL , POPLINE , Global Health Library and reference lists of eligible studies. Selection criteria All study types investigating pharmacokinetic properties of Mg SO 4 in women with pre‐eclampsia and/or eclampsia. Data collection and analysis Two authors extracted data on basic pharmacokinetic parameters reflecting the different aspects of absorption, bioavailability, distribution and excretion of Mg SO 4 according to identified dosing regimens. Main results Twenty‐eight studies investigating pharmacokinetic properties of 17 Mg SO 4 regimens met our inclusion criteria. Most women (91.5%) in the studies had pre‐eclampsia. Baseline serum magnesium concentrations were consistently <1 mmol/l across studies. Intravenous loading dose between 4 and 6 g was associated with a doubling of this baseline concentration half an hour after injection. Maintenance infusion of 1 g/hour consistently produced concentrations well below 2 mmol/l, whereas maintenance infusion at 2 g/hour and the Pritchard intramuscular regimen had higher but inconsistent probability of producing concentrations between 2 and 3 mmol/l. Volume of distribution of magnesium varied (13.65–49.00 l) but the plasma clearance was fairly similar (4.28–5.00 l/hour) across populations. Conclusion The profiles of Zuspan and Pritchard regimens indicate that the minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted level. Exposure–response studies to identify effective alternative dosing regimens should target concentrations achievable by these standard regimens. Tweetable abstract Minimum effective serum magnesium concentration for eclampsia prophylaxis is lower than the generally accepted therapeutic level.